Vaginal Bleeding Clinical Trial
Official title:
Use of Chitosan Powder in Loop Electrosurgical Excision Procedure to Reduce Postoperative Complications: A Randomized Controlled Trial
Verified date | May 2024 |
Source | Erzincan Military Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Early treatment of cervical intraepithelial neoplasia (CIN) II-III gives rise to a decrease in the incidence of invasive cervical cancer. Though there is no obvious consensus from randomized studies as to the optimal management of CIN II-III, loop electrosurgical excision procedure (LEEP) is the most extensively used method because of its technical ease, inexpensive, steep learning curve, and low rate of complications. In spite of these benefits, current literature suggests that some patients experience some complications such as postoperative vaginal bleeding, abnormal vaginal discharge, abdominal pain, and infection. These adversely affect the recovery period, increase patient anxiety, readmission to the hospital for further treatment and encumber patients' daily life. Postoperative vaginal bleeding (PVB) is one of the most common and unpleasant of these complications. Its incidence has been reported to vary between 2% to 78%. Many different types of treatments have been applied to avert or diminish PVC such as the use of vasopressin, tranexamic acid, Monsel's solution, and local hemostats (e.g., TachoSil or Tisseel), but these attempts have failed to show precise benefits over routine clinical approaches. Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect. The current literature concerning the influence of using chitosan after the LEEP is limited to only one trial. The authors of that study reported that using chitosan after the LEEP can reduce vaginal bleeding and enhancing wound healing. However, that study has some limitations. Therefore, investigators designed this randomized trial to assess the effect of local chitosan implementation on postoperative vaginal bleeding and wound healing in LEEP
Status | Completed |
Enrollment | 130 |
Est. completion date | May 17, 2024 |
Est. primary completion date | March 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - women were aged > 21 years old - women were not pregnant - women who were undergoing LEEP. Exclusion Criteria: - Women with pelvic infection - Women with abnormal vaginal bleeding - Women with coagulopathy - Women with chronic pain syndromes - Women with psychiatric disorders - Women with the previous hysterectomy with removal of the cervix, - Women with a history of cervical cancer - Women who could not complete follow-up calls |
Country | Name | City | State |
---|---|---|---|
Turkey | Kemal Güngördük | Mentese | Mugla |
Turkey | Mugla Sitki Kocman University Education and Research Hospital | Mugla |
Lead Sponsor | Collaborator |
---|---|
Erzincan Military Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | median early postoperative blood loss | early postoperative blood loss using the difference in hematocrit values after LEEP and 24 h after the procedure according to the following formula: estimated blood loss = estimated blood volume × (hematocrit 1 - hematocrit 2) / hematocrit 1, where the estimated blood volume in milliliters = body weight in kilograms × 85 | 6 hours | |
Secondary | Wound healing score | The imagine J software program (https://imagej.net/ij/) was used to measure the area of wounds. In order to determine the rate of wound healing, the formula used is [(initial area of treatment wound - remaining wound area)/initial area of treatment wound] × 100%. | 1-4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00921778 -
Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern
|
N/A | |
Completed |
NCT02472184 -
Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy
|
N/A | |
Recruiting |
NCT04612881 -
Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.
|
||
Completed |
NCT00339651 -
Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
|
||
Withdrawn |
NCT04933240 -
Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial
|
Phase 4 | |
Completed |
NCT05668806 -
RWE Study in the Treatment of Cervical Lesions of Various Etiology
|
||
Terminated |
NCT04277962 -
Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial
|
N/A | |
Active, not recruiting |
NCT02752282 -
Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction
|
N/A | |
Completed |
NCT02385747 -
Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding
|
N/A | |
Completed |
NCT03856307 -
Reliability of Simple Sonographic Findings Acquired With Hand-held Apparatuses to Inform Obstetric Diagnosis
|
||
Completed |
NCT01868308 -
Screening To Obviate Preterm Birth
|
N/A | |
Completed |
NCT05840471 -
Tranexamic Acid as an Intervention in Abruptio Placenta
|
N/A | |
Not yet recruiting |
NCT05645848 -
The Rate and Predictors of Vaginal Bleeding Among Women With Placenta Previa
|
||
Completed |
NCT03074903 -
Does Skyla Insertion Timing Impact Bleeding?
|
N/A |